BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen X, Sheikh K, Nakajima E, Lin CT, Lee J, Hu C, Hales RK, Forde PM, Naidoo J, Voong KR. Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies. Oncologist 2021. [PMID: 34251728 DOI: 10.1002/onco.13900] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
Number Citing Articles
1 Lan F, Fan B, Wang L, Xia L, Zhang T, Li W, Mao Y. The CURB65 score predicted 180-day mortality of non-small cell lung carcinoma patients with immune checkpoint inhibitor-associated pneumonitis: A pilot retrospective analysis. Front Oncol 2022;12:927858. [DOI: 10.3389/fonc.2022.927858] [Reference Citation Analysis]
2 Cortiula F, Reymen B, Peters S, Van Mol P, Wauters E, Vansteenkiste J, De Ruysscher D, Hendriks LEL. Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches. Ann Oncol 2022:S0923-7534(22)01742-2. [PMID: 35777706 DOI: 10.1016/j.annonc.2022.06.013] [Reference Citation Analysis]
3 Capaccione KM, Valiplackal JP, Huang A, Roa T, Fruauff A, Liou C, Kim E, Khurana S, Maher M, Ma H, Ngyuen P, Mak S, Dumeer S, Lala S, D'souza B, Laifer-Narin S, Desperito E, Ruzal-Shapiro C, Salvatore MM. Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review. Acad Radiol 2022:S1076-6332(22)00171-4. [PMID: 35382975 DOI: 10.1016/j.acra.2022.03.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Fitzpatrick O, Naidoo J. Immunotherapy for Stage III NSCLC: Durvalumab and Beyond. Lung Cancer (Auckl) 2021;12:123-31. [PMID: 34754256 DOI: 10.2147/LCTT.S305466] [Cited by in F6Publishing: 2] [Reference Citation Analysis]